Bisphosphonate treatment of lytic bone metastases

Allan Lipton, James R. Berenson

Research output: Contribution to journalEditorial

11 Citations (Scopus)

Abstract

Tumour-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by tumour products or indirectly through an influence on other cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Pamidronate is a second-generation aminobisphosphonate that is a potent inhibitor of osteoclastic activity. In multiple myeloma, a phase III study has shown that the proportion of patients at the end of 21 months who had any skeletal event was significantly lower in the pamidronate group (38%) than in the placebo group (58%). The therapeutic benefit was independent of the type of antimyeloma chemotherapy. Patients who received pamidronate had significant decrease in bone pain and delayed deterioration in performance status and quality of life. Overall there was no survival advantage in patients who received pamidronate. In similar fashion, in 2 phase III breast cancer trials, patients who received pamidronate had fewer skeletal events, decrease in bone pain and analgesic use, and slower deterioration of performance status that in those patients receiving placebo. Again, there was no survival advantage in these patients. Recent studies suggest that the bisphosphonates clodronate can prevent the development of bone metastases in patients with breast cancer.

Original languageEnglish (US)
Pages (from-to)241-246
Number of pages6
JournalDrugs and Aging
Volume14
Issue number4
DOIs
StatePublished - May 5 1999

Fingerprint

pamidronate
Diphosphonates
Neoplasm Metastasis
Bone and Bones
Osteoclasts
Therapeutics
Placebos
Clodronic Acid
Breast Neoplasms
Pain
Osteolysis
Survival
Bone Diseases
Bone Development
Bone Resorption
Multiple Myeloma
Analgesics
Neoplasms
Quality of Life
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Geriatrics and Gerontology
  • Pharmacology (medical)

Cite this

Lipton, Allan ; Berenson, James R. / Bisphosphonate treatment of lytic bone metastases. In: Drugs and Aging. 1999 ; Vol. 14, No. 4. pp. 241-246.
@article{cdabb880360f4e998d82ef26978003dc,
title = "Bisphosphonate treatment of lytic bone metastases",
abstract = "Tumour-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by tumour products or indirectly through an influence on other cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Pamidronate is a second-generation aminobisphosphonate that is a potent inhibitor of osteoclastic activity. In multiple myeloma, a phase III study has shown that the proportion of patients at the end of 21 months who had any skeletal event was significantly lower in the pamidronate group (38{\%}) than in the placebo group (58{\%}). The therapeutic benefit was independent of the type of antimyeloma chemotherapy. Patients who received pamidronate had significant decrease in bone pain and delayed deterioration in performance status and quality of life. Overall there was no survival advantage in patients who received pamidronate. In similar fashion, in 2 phase III breast cancer trials, patients who received pamidronate had fewer skeletal events, decrease in bone pain and analgesic use, and slower deterioration of performance status that in those patients receiving placebo. Again, there was no survival advantage in these patients. Recent studies suggest that the bisphosphonates clodronate can prevent the development of bone metastases in patients with breast cancer.",
author = "Allan Lipton and Berenson, {James R.}",
year = "1999",
month = "5",
day = "5",
doi = "10.2165/00002512-199914040-00001",
language = "English (US)",
volume = "14",
pages = "241--246",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Adis International Ltd",
number = "4",

}

Bisphosphonate treatment of lytic bone metastases. / Lipton, Allan; Berenson, James R.

In: Drugs and Aging, Vol. 14, No. 4, 05.05.1999, p. 241-246.

Research output: Contribution to journalEditorial

TY - JOUR

T1 - Bisphosphonate treatment of lytic bone metastases

AU - Lipton, Allan

AU - Berenson, James R.

PY - 1999/5/5

Y1 - 1999/5/5

N2 - Tumour-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by tumour products or indirectly through an influence on other cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Pamidronate is a second-generation aminobisphosphonate that is a potent inhibitor of osteoclastic activity. In multiple myeloma, a phase III study has shown that the proportion of patients at the end of 21 months who had any skeletal event was significantly lower in the pamidronate group (38%) than in the placebo group (58%). The therapeutic benefit was independent of the type of antimyeloma chemotherapy. Patients who received pamidronate had significant decrease in bone pain and delayed deterioration in performance status and quality of life. Overall there was no survival advantage in patients who received pamidronate. In similar fashion, in 2 phase III breast cancer trials, patients who received pamidronate had fewer skeletal events, decrease in bone pain and analgesic use, and slower deterioration of performance status that in those patients receiving placebo. Again, there was no survival advantage in these patients. Recent studies suggest that the bisphosphonates clodronate can prevent the development of bone metastases in patients with breast cancer.

AB - Tumour-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by tumour products or indirectly through an influence on other cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Pamidronate is a second-generation aminobisphosphonate that is a potent inhibitor of osteoclastic activity. In multiple myeloma, a phase III study has shown that the proportion of patients at the end of 21 months who had any skeletal event was significantly lower in the pamidronate group (38%) than in the placebo group (58%). The therapeutic benefit was independent of the type of antimyeloma chemotherapy. Patients who received pamidronate had significant decrease in bone pain and delayed deterioration in performance status and quality of life. Overall there was no survival advantage in patients who received pamidronate. In similar fashion, in 2 phase III breast cancer trials, patients who received pamidronate had fewer skeletal events, decrease in bone pain and analgesic use, and slower deterioration of performance status that in those patients receiving placebo. Again, there was no survival advantage in these patients. Recent studies suggest that the bisphosphonates clodronate can prevent the development of bone metastases in patients with breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0032949816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032949816&partnerID=8YFLogxK

U2 - 10.2165/00002512-199914040-00001

DO - 10.2165/00002512-199914040-00001

M3 - Editorial

C2 - 10319239

AN - SCOPUS:0032949816

VL - 14

SP - 241

EP - 246

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 4

ER -